[go: up one dir, main page]

PE20110152A1 - Nuevos derivados de sulfamida sustituida - Google Patents

Nuevos derivados de sulfamida sustituida

Info

Publication number
PE20110152A1
PE20110152A1 PE2011000064A PE2011000064A PE20110152A1 PE 20110152 A1 PE20110152 A1 PE 20110152A1 PE 2011000064 A PE2011000064 A PE 2011000064A PE 2011000064 A PE2011000064 A PE 2011000064A PE 20110152 A1 PE20110152 A1 PE 20110152A1
Authority
PE
Peru
Prior art keywords
new substitute
sulfamide derivatives
refers
sulfamide
compounds
Prior art date
Application number
PE2011000064A
Other languages
English (en)
Inventor
David F Mccomsey
Michael H Parker
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20110152A1 publication Critical patent/PE20110152A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE SULFAMIDA DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C4) U -O-FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALCOXI(C1-C4), CN, ENTRE OTROS. SIENDO UN COMPUESTO PREFERIDO: (2S)-(-)-N'-ACETIL-N-(6-CLORO-2,3-DIHIDRO-BENZO[1,4]DIOXIN-2-ILMETIL)-SULFAMIDA. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ANSIEDAD, DEPRESION BIPOLAR, EPILEPSIA, MIGRANA
PE2011000064A 2008-07-22 2009-07-15 Nuevos derivados de sulfamida sustituida PE20110152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8265408P 2008-07-22 2008-07-22

Publications (1)

Publication Number Publication Date
PE20110152A1 true PE20110152A1 (es) 2011-03-07

Family

ID=41050370

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000064A PE20110152A1 (es) 2008-07-22 2009-07-15 Nuevos derivados de sulfamida sustituida

Country Status (27)

Country Link
US (1) US8815939B2 (es)
EP (1) EP2326635B1 (es)
JP (1) JP2011529056A (es)
KR (1) KR20110044757A (es)
CN (1) CN102159563B (es)
AR (1) AR072586A1 (es)
AU (1) AU2009274266B2 (es)
BR (1) BRPI0915991A2 (es)
CA (1) CA2731295A1 (es)
CL (1) CL2011000144A1 (es)
CO (1) CO6300863A2 (es)
CR (1) CR20110100A (es)
EA (1) EA020050B1 (es)
EC (1) ECSP11010779A (es)
ES (1) ES2434873T3 (es)
HN (1) HN2011000235A (es)
IL (1) IL210592A0 (es)
MX (1) MX2011000822A (es)
NI (1) NI201100026A (es)
NZ (1) NZ590456A (es)
PE (1) PE20110152A1 (es)
SV (1) SV2011003815A (es)
TW (1) TW201014839A (es)
UA (1) UA103901C2 (es)
UY (1) UY32000A (es)
WO (1) WO2010011548A1 (es)
ZA (1) ZA201101371B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
CA2578407A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
MX2007014613A (es) * 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
EP2026790A2 (en) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
WO2010008776A2 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems
ES2704928T3 (es) * 2013-12-12 2019-03-20 Bio Pharm Solutions Co Ltd Compuestos derivados de sulfamato para su uso en el tratamiento o alivio del dolor
CN105979942B (zh) * 2013-12-12 2018-12-07 比皮艾思药物研发有限公司 用于治疗或缓解疼痛的氨基磺酸酯衍生物
US9937145B2 (en) 2013-12-12 2018-04-10 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compound for use in preventing or treating epilepsy
BR112023003473A2 (pt) 2020-08-31 2023-04-11 Bio Pharm Solutions Co Ltd Compostos de carbamato de alquil fenila para o uso na prevenção ou no tratamento de doença neurodegenerativa
BR112023004354A2 (pt) 2020-09-10 2023-04-04 Bio Pharm Solutions Co Ltd Compostos derivados de sulfamato para uso no tratamento ou alívio de um transtorno psiquiátrico

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2527861A (en) 1948-05-07 1950-10-31 Monsanto Chemicals Mono alkyl sulfamides
BE636655A (es) 1962-09-14
DE1211166B (de) 1962-11-20 1966-02-24 Ciba Geigy Verfahren zur Herstellung neuer Sulfamide
US3318952A (en) 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3320314A (en) 1964-01-22 1967-05-16 Sandoz Ag Chlorobenzyl sulfamides
US3383414A (en) 1964-08-26 1968-05-14 Sandoz Ag Benzocycloalkyl sulfamides
DE1542785A1 (de) 1965-07-24 1970-05-06 Bayer Ag Insekten- und milbenabweisende Mittel
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621096A (en) 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2022370A1 (de) 1970-05-08 1971-12-02 Bayer Ag N-Fluordichlormethylthio-sulfamidsaeure-Derivate,Verfahren zu ihrer Herstellung und ihre mikrobizide und fungizide Verwendung
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
FR2479825A1 (fr) 1980-04-04 1981-10-09 Fabre Sa Pierre Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
DE3901550A1 (de) * 1989-01-20 1990-07-26 Basf Ag Neue tetrahydroindazole mit phenyletherstruktur
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5273993A (en) 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5192785A (en) 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5189179A (en) 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
CA2054339C (en) 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
GB9026998D0 (en) 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
US5120758A (en) 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors
GB9104890D0 (en) 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
AU651244B2 (en) 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
DE69434652T2 (de) 1993-12-23 2007-03-01 Ortho-Mcneil Pharmaceutical, Inc. Antikonvulsive pseudofructopyranose sulfamate
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
CA2216648A1 (en) 1995-02-15 1996-08-22 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
JP3235448B2 (ja) 1995-03-24 2001-12-04 ダイソー株式会社 １，４−ベンゾジオキサン誘導体の製法
US5998380A (en) 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
AU2587297A (en) 1996-03-25 1997-10-17 Eli Lilly And Company Method for treating pain
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
WO1998000124A1 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
SK284305B6 (sk) 1996-06-28 2005-01-03 Ortho-Mcneil Pharmaceutical, Inc. Liečivo na liečbu obezity
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
CN1205193C (zh) 1996-08-14 2005-06-08 G·D·瑟尔公司 4－[5－甲基－3－苯基异噁唑－4－基]苯磺酰胺的晶型
ATE293458T1 (de) 1996-08-23 2005-05-15 Algos Pharm Corp Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
US20020015713A1 (en) 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5935933A (en) 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
AU9021298A (en) 1997-08-15 1999-03-08 Carolyn Ann Fairbanks Agmatine as a treatment for neuropathic pain
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
WO2000001376A2 (en) 1998-07-02 2000-01-13 Eisai Co., Ltd Pharmaceutical compositions and their uses for treatment of demyelinating disorders
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
MXPA01007350A (es) 1999-01-19 2003-06-06 Johnson & Johnson Derivados anticonvulsivos utiles en el tratamiento de cefalea acuminada.
AU3582600A (en) 1999-01-21 2000-08-07 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating transformed migraine
EP1158973B1 (en) 1999-02-24 2005-05-04 University Of Cincinnati Use of sulfamate derivatives for treating impulse control disorders
WO2000054588A1 (en) 1999-03-15 2000-09-21 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
WO2000061140A1 (en) 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
MXPA01010218A (es) 1999-04-08 2002-03-27 Johnson & Johnson Derivados anticonvulsivos utiles para disminuir lipidos.
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
JP2003521471A (ja) 1999-04-08 2003-07-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 慢性神経変性疾患を処置することに有用な抗痙攣薬誘導体
ATE275950T1 (de) 1999-05-04 2004-10-15 Keith R Edwards Intravenösen verabreichung von valproat zur behandlung von migränekopfschmerzen
ES2542892T3 (es) 1999-06-14 2015-08-12 Vivus, Inc. Terapia de combinación para el tratamiento de hipertensión asociada con la obesidad
KR100758609B1 (ko) 1999-08-20 2007-09-13 오르토-맥네일 파마슈티칼, 인코퍼레이티드 트라마돌 화합물 및 항경련 약물을 포함하는 조성물
FR2803848B1 (fr) 2000-01-19 2002-02-15 Adir Nouveaux derives de benzenesulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6322503B1 (en) 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
PL365680A1 (en) 2000-07-07 2005-01-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x
DE10035227A1 (de) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
US6627653B2 (en) 2000-08-02 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
US7256184B2 (en) 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
AU2002240235B2 (en) 2001-01-30 2006-07-06 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
JP2004536071A (ja) 2001-05-25 2004-12-02 クイーンズ　ユニバーシティ　アット　キングストン 複素環ベータアミノ酸およびそれらの抗癲癇誘発剤としての使用
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
RU2226357C1 (ru) 2003-02-12 2004-04-10 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева Способ диагностики эпилепсии у пациентов с доклинической стадией болезни
RU2246727C2 (ru) 2003-02-12 2005-02-20 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева (НИПИ) Способ диагностики доклинической стадии эпилепсии
AU2004231070B2 (en) 2003-04-10 2008-02-14 Amgen, Inc. Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
JP4373343B2 (ja) 2003-04-16 2009-11-25 スミスクライン・ビーチャム・コーポレイション ペプチドデホルミラーゼ阻害剤
JPWO2004093912A1 (ja) 2003-04-23 2006-07-13 協和醗酵工業株式会社 好中球性炎症疾患の予防および／または治療剤
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
US7576122B2 (en) 2003-09-02 2009-08-18 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
TW200612905A (en) 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2006010008A1 (en) 2004-06-22 2006-01-26 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
WO2006010750A1 (en) 2004-07-28 2006-02-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US20060276528A1 (en) 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
CA2578407A1 (en) 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
BRPI0610046A2 (pt) 2005-04-22 2010-05-25 Wyeth Corp derivados de benzodioxano e benzodioxolano e usos destes
MX2007014613A (es) 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
US20070155824A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155823A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155827A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070191459A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191449A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191452A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
US20070191450A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191461A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191474A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191451A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191453A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191460A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
TW200738669A (en) 2006-02-22 2007-10-16 Janssen Pharmaceutica Nv Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
EP2026790A2 (en) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
WO2007137164A2 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy and related disorders
WO2009089210A1 (en) 2008-01-07 2009-07-16 Janssen Pharmaceutica N. V. Preparation of sulfamide derivatives
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
KR20100126536A (ko) 2008-03-26 2010-12-01 얀센 파마슈티카 엔.브이. 벤조-융합된 다이옥신 유도체의 제조방법
US20090247618A1 (en) 2008-03-26 2009-10-01 Ballentine Scott A Process for preparation of benzo-fused heteroaryl derivatives
MX2010010595A (es) 2008-03-26 2010-10-25 Janssen Pharmaceutica Nv Proceso para la preparacion de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihid ro-1,4-benzodioxin-2il)metil-sulfamida.
WO2010008776A2 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Disposable patch and reusable sensor assembly for use in medical device localization and mapping systems

Also Published As

Publication number Publication date
HK1158198A1 (en) 2012-07-13
CR20110100A (es) 2011-07-06
AU2009274266A1 (en) 2010-01-28
MX2011000822A (es) 2011-02-25
CO6300863A2 (es) 2011-07-21
UA103901C2 (ru) 2013-12-10
EA201170240A1 (ru) 2011-10-31
ECSP11010779A (es) 2011-02-28
CN102159563A (zh) 2011-08-17
US8815939B2 (en) 2014-08-26
IL210592A0 (en) 2011-03-31
WO2010011548A1 (en) 2010-01-28
AU2009274266B2 (en) 2014-05-15
EA020050B1 (ru) 2014-08-29
US20100063138A1 (en) 2010-03-11
NZ590456A (en) 2012-06-29
EP2326635B1 (en) 2013-08-28
AR072586A1 (es) 2010-09-08
UY32000A (es) 2010-01-29
TW201014839A (en) 2010-04-16
JP2011529056A (ja) 2011-12-01
HN2011000235A (es) 2013-09-02
CN102159563B (zh) 2013-12-11
BRPI0915991A2 (pt) 2019-09-24
EP2326635A1 (en) 2011-06-01
ZA201101371B (en) 2012-07-25
KR20110044757A (ko) 2011-04-29
NI201100026A (es) 2011-09-07
CA2731295A1 (en) 2010-01-28
CL2011000144A1 (es) 2011-09-23
SV2011003815A (es) 2011-03-31
ES2434873T3 (es) 2013-12-17

Similar Documents

Publication Publication Date Title
PE20110152A1 (es) Nuevos derivados de sulfamida sustituida
PE20121182A1 (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
PE20070519A1 (es) Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
PE20081831A1 (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20140934A1 (es) Derivados de pirazol
PE20130235A1 (es) Derivados de aminopirimidina como moduladores de la lrrk2
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20110060A1 (es) Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
PE20091014A1 (es) Compuestos espiro y uso farmaceutico de los mismos
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
AR047529A1 (es) Compuestos de quinolina sustituidos
PE20081579A1 (es) Derivados de benzamida como agonistas del receptor
PE20120834A1 (es) Derivados de furopirimidindiona como moduladores de trpa1
PE20071251A1 (es) Derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
NO20091025L (no) Arylsulfonamider med analgesisk virkning
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
PE20110215A1 (es) Derivados de 4,5-dihidro-oxazol-2-ilo
PE20091692A1 (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
PE20081160A1 (es) Arilsulfonil-pirrolidinas como inhibidores 5-ht6
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
EA200970506A1 (ru) Применение индазолметоксиалкановой кислоты для снижения уровней триглицеридов, холестерина и глюкозы
PE20130512A1 (es) Compuesto, composicion farmaceutica, uso de un compuesto y metodo para el tratamiento de los trastornos asociados a los receptores serotoninergicos 5-ht1a y 5-ht2a

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed